Posted in | News | Water

Illinois Electric Utility Gets Approval to Use Calgon Carbon Product for Mercury Removal

Calgon Carbon Corporation has announced that the Illinois Environmental Protection Agency (ILEPA) has granted Midwest Generation approval to use Calgon Carbon's FLUEPAC MC Plus activated carbon to control mercury emissions from plants that burn coal to produce electricity.

The decision by the ILEPA adds Calgon Carbon's FLUEPAC MC Plus activated carbon to the list of activated carbon products that Midwest Generation may use for mercury control. Midwest Generation is one of the largest independent power producers in the U.S., generating enough electricity to meet the needs of more than eight million households.

An ILEPA rule, promulgated in December 2006, identifies activated carbon as an acceptable method for mercury removal from coal-fired power plants and mandates that all electric utilities in the state meet specific mercury reduction requirements by July 1, 2009. By mid-2009, electric utilities in Illinois are expected to require 70 to 90 million pounds of activated carbon per year to meet the state's mercury removal rule.

Commenting on the announcement, Robert P. O'Brien, senior vice president - Americas for Calgon Carbon, said, "We are very pleased with the Illinois EPA's decision. It recognizes our FLUEPAC product's effectiveness in controlling mercury emissions from coal-fired power plants. We are hopeful that this approval will prompt other electric utilities in Illinois to request permission to use our activated carbon products to meet their state's mercury reduction requirements."

Calgon Carbon Corporation, headquartered in Pittsburgh, Pennsylvania, is a global leader in services and solutions for making water and air safer and cleaner.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.